Abstract Presenilins (PSs) are catalytic components of the c-secretase complex that produces Ab peptides. Substrates of c-secretase are membrane-bound protein fragments deriving from the cleavage of extracellular sequence of cell surface proteins. APP-derived c-secretase substrates are cleaved at gamma (c) sites to produce Ab while cleavage at the epsilon (e) site produces AICD proposed to function in transcription. In addition to APP, c-secretase promotes the ecleavage of a large number of cell surface proteins producing cytosolic peptides shown to function in cell signaling. A common hypothesis suggests that Alzheimer's disease (AD) is caused by Ab peptides or their products. Treatment of patients with inhibitors of Ab production however, showed no therapeutic benefits while inducing cytotoxicity. Similarly, treatments with anti-Ab antibodies yielded disappointing results. Importantly, recent evidence shows that PS familial AD (FAD) mutations cause a loss of c-secretase cleavage activity at e site of substrates thus inhibiting production of biologically important cell signaling peptides while promoting accumulation of membrane-bound cytotoxic substrates. These data support a hypothesis that FAD mutations may increase neurotoxicity by inhibiting the csecretase-catalyzed e cleavage of substrates thus interfering with cell signaling while also promoting accumulation of cytotoxic peptides. Similar mechanisms may explain csecretase inhibitor-associated toxicities observed in clinical trials. Here we discuss evidence that FAD neurodegeneration may be caused by loss of c-secretase cleavage function at e sites of substrates.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system (CNS) leading to the most common form of age-associated dementia. Clinical symptoms of AD include loss of recent memory, faulty judgment, personality changes and progressive loss of reasoning. The neuropathology of AD is characterized by large numbers of neuritic plaques (NPs) and neurofibrillary tangles (NFTs) in the brain striatum and neocortex [32] . It is now believed that dementia is caused by neuronal and synapse losses in the affected areas of the CNS. NPs are extracellular structures containing a core of amyloid depositions of aggregated fibrillar Ab protein surrounded by dystrophic neuritis, astrocytes and reactive microglia. In contrast to NPs, NFTs are intracellular aggregates of paired helical filaments of hyper-phosphorylated tau protein. In addition, AD patients often display high levels of Ab amyloid depositions on the walls of cerebral blood vessels, a condition termed cerebrovascular amyloidosis (CVA) [20] . Most AD cases are sporadic affecting patients over 65 or 70 years old but about 5 % are classified as familial Alzheimer's disease (FAD) because they are due to specific genetic mutations. FADs occur mostly at younger ages and follow a more aggressive clinical course than sporadic AD. The brain neuropathology however, is similar in sporadic and familial AD, suggesting the involvement of common cellular mechanisms in both forms of the disease.
Currently, a definite diagnosis of the disease is made after clinical symptoms are combined with post-mortem examination of brain tissue for detection of plaques and tangles, the pathological hallmarks of the disease.
Despite intense research efforts, the cause of the accelerated neuronal degeneration that causes dementia remains unclear although it is now believed that the disease is driven by both environmental and genetic factors. Presently, age and the apolipoprotein allele E4 are the most important risk factors for sporadic AD. In contrast, FAD is driven by specific genetic mutations localized in at least three genetic loci including the genes for the amyloid precursor protein (APP) [11] , presenilin1 (PS1), [42] and PS2 [25] . APP is important to all forms of AD because in addition to its contribution to FAD, it is the precursor of the Ab peptides that form the amyloid depositions used to define the disorder [37] . APP is also important to Down syndrome (DS) as almost all patients over the age of 40 develop brain neuropathologies similar to AD including amyloid depositions [50] . Localization of the APP gene on chromosome 21 revealed a direct genetic linkage between these two disorders [38] . It is important to note however, that neither NPs nor NFTs are specific to AD as both pathological structures are also found in normal aged people, usually at lower numbers compared to AD. In addition, NFTs are found in other neurodegenerative disorders including frontotemporal dementia (FTD) and Parkinson's disease. The presence of NFTs in neurodegenerative disorders of distinct etiology suggests that tau hyperphosphorylation and aggregation may represent a reaction to neurotoxicity induced by genetic lesions or environmental factors such as oxidative and excitotoxic stresses.
The Etiology of AD
Following molecular characterization of brain amyloid depositions and NFTs, the two pathological hallmarks of AD, research focused mainly on Ab peptides and their soluble and insoluble derivatives as the main causative agents of dementia. Ab peptides are a family of small proteins with heterogenous ends containing 35-43 amino acids with Ab40 and 42 being the predominant species [30, 31] . Under conditions that favor aggregation, Ab peptides aggregate to form amyloid fibrils that precipitate in NPs found in interneuronal spaces and in blood vessels as CVA. Ab peptides are derived from the amyloidogenic processing of APP, a type I transmemebrane protein, through the combined action of b (beta) and c (gamma) secretases (for detailed review see [36] ). b-secretase [46] acts on extracellular APP to produce peptide C99 that is then processed by the PS/c-secretase complex [51] at c sites to produce the Ab peptides found in amyloid depositions ( from the a-cleavage are usually referred to as CTF1s [29] . Products of both a and b cleavages are processed by c-secretase. Cleavage at c sites produces Ab-like peptides. Cleavage at e-site produces the soluble cytosolic CTF2 (or ICD for APP) peptides shown to function in signal transduction (for more details see [6] . N and C; protein Nand C-termini respectively (Color figure online)
Neurochem Res (2014) 39:570-575 571 non-amyloidogenic processing, APP is cleaved by asecretase, usually an ADAM, within the Ab sequence thus inhibiting production of Ab peptides [1] . a-Secretasederived APP fragments are also processed by PS/c-secretase at the e site ( Fig. 1) , a process that results in the production of intracellular peptides containing the carboxyl-terminal fragment (CTF) of APP. Recent work revealed a number of cell surface proteins and receptors that, similar to APP, are processed by c-secretase at e sites producing intracellular CTF peptides (also called intracellular domains, ICDs). Importantly, a number of these peptides have been shown to act as signal transduction and gene expression factors [28] . Despite extensive research efforts in the last two decades there is no agreement on the proposed neurotoxicity of NPs and many workers doubt these structures are the main causative agents of AD [33, 44] . Although amyloid depositions may contribute secondarily to neuronal dysfunction, it now seems unlikely that these are the main cause of the AD neurodegeneration as studies have failed to show significant correlations between brain NPs and degree of dementia or neuronal loss [10, 14, 16] . Importantly, amyloid depositions at levels similar to those seen in AD are often detected in normal aged individuals [14, 16] , and transgenic (Tg) animals with high levels of brain amyloid deposits show no significant neurodegeneration [22] . Studies in humans showed that clearance of NPs resulted neither in cognitive improvement nor in decreased rate of mental deterioration [21] suggesting that amyloid deposits are not the driving force of neurodegeneration and cognitive decline in AD. It seems therefore unlikely that clearance of brain amyloid depositions will result in significant improvements of AD patients.
The inability of amyloid-based theories to explain AD prompted the development of the soluble Ab oligomer theories that posit soluble oligomers of extracellular or intracellular Ab42 represent the neurotoxic forms of Ab. Indeed, evidence suggests that soluble oligomeric Ab may interfere with synaptic function in vitro or memory function in experimental animal models [13, 47] . Most of these models however, are based on overexpression of exogenous APP, an artificial condition that does not apply to AD where there is no APP overexpression [37] . In addition, behavioral abnormalities in animal models overexpressing APP cannot be unambiguously assigned to soluble Ab or oligomers as APP is metabolized to a large number of derivatives some of which, such as C-terminal fragments, have been shown to be cytotoxic. It is thus unclear whether the behavioral abnormalities detected in Tg APP mice are due to specific Ab species or to toxicities associated with the overexpression of exogenous APP. Furthermore, there is no evidence for the existence of soluble toxic Ab oligomeric species specific to AD. Regarding the in vitro neurotoxicity of Ab42, it is important to note that this neurotoxicity becomes detectable when Ab is used at concentrations which are at least ten thousand times higher than the peptide concentrations found in vivo (usually less than 500 pM). Presently there is little evidence of ADassociated increases in the levels of soluble Ab or its oligomers. Absence of data supporting disease-associated increases in soluble toxic Ab species is a serious weakness to the theory that such oligomers cause the neurodegeneration of AD.
FAD, Presenilins and Ab
Mutations in three distinct genes, presenilin-1 (PS-1), PS2 and APP, have been implicated as causative agents of FAD, with mutations in the PS1 gene responsible for most cases. To date more than 150 FAD mutations have been linked to PS1 gene. Although early reports suggested that FAD mutations increase production of neurotoxic Ab42 by causing a gain of c-secretase function, the activity involved in its production [9, 12, 40] , recent work [8, 43] showed that many PS1 FAD mutants do not increase Ab. Similarly, reports that FAD mutations increase the Ab42/40 ratio may need further examination because many FAD mutants fail to increase this ratio [43] and although the APP Swedish FAD mutation causes a robust increase in both Ab42 and Ab40 due to increases in b-secretase cleavage, it does not alter the Ab42/40 ratio [17] . Additional evidence indicate that affected individuals carrying PS1 FAD mutants have no abnormalities in neither the in vivo levels of soluble Ab nor the Ab42/40 ratio [7] .
That many FAD mutations have no significant effect on Ab supports the hypothesis that these mutations promote neurodegeneration independent of Ab peptides [43] . The neurodegeneration caused by FAD mutants suggests the WT proteins play critical roles in neuronal survival. FAD mutations may interfere with these neuronal survival activities, thus promoting neuronal cell death. Although the autosomal dominant mode of FAD transmission seems consistent with the hypothesis that FAD mutants cause gain of a toxic function, such a specific gain is unexpected for a large number of FAD mutations distributed throughout the PS1 polypeptide chain. A more parsimonious explanation is the suggestion that the FAD mutant alleles cause a dominant negative loss of function. The protein product of the mutant allele could for example physically interact with and inactivate the product of the wild type allele. This mechanism of ''allelic interference in FAD'' [36] is supported by recent evidence that FAD mutations inhibit biological functions of PS and that PSs, as well as APP, form dimmers [39, 41] . Such a mechanism would be consistent with both the autosomal dominant transmission of FAD neurodegeneration and absence of haploinsufficiency mutations in FAD.
Role of c-Secretase-Dependent e Cleavage of Proteins in Cell Signaling and AD
Recent evidence shows that in addition to amyloidogenic c-cleavages of APP, the PS/c-secretase system promotes the e-cleavage of a number of type I transmembrane proteins, including APP, cadherins, Notch1 and EphB receptors and CD44. The e-cleavage occurs seven to ten amino acid residues downstream from the c-cleavages releasing soluble cytosolic peptides containing the cytosolic carboxyl-terminal fragments of cleaved substrates (Fig. 1) . To date more than 30 cell surface transmembrane proteins have been shown to be cleaved at the e-site by c-secretase, producing soluble peptides shown to migrate to the nucleus where they act as regulators of gene expression while others remain in the cytoplasm where they regulate metabolism of transcription factors [28] . Together, these data revealed that in addition to producing Ab, the csecretase system plays central roles in the production of peptides with important biological functions in signal transduction and gene expression.
Recent work reveals that many PS1 FAD mutants inhibit production of CTF2 peptides indicating these mutants cause a loss of c-secretase cleavage function at the e site of substrates such as N-cadherin, efnB2, and EphB2 [19, 26, 29, 49] . These data support the hypothesis that PS FAD mutations contribute to neurotoxicity by inhibiting production of peptides with useful cellular functions [18, 29] . Furthermore, by reducing the e-cleavage, PS FAD mutations promote accumulation of membrane-bound CTF1 fragments, the substrates of c-secretase [26, 29] . Recent reports indicate that increased levels of CTF1s, such as those derived from APP and netrin, are associated with increased cytotoxicity [2, 23, 27] and their accumulation may contribute to the neurodegeneration associated with FAD mutations. Presently, it is unclear why CTF1s are toxic. It is possible that accumulation of high levels of these transmembrane peptides interferes with the movements of receptors and other factors on the plane of the membrane with toxic consequences [6] . Thus, PS FAD mutations may promote neurotoxicity by both, reducing production of biologically active CTF2 peptides and increasing accumulation of toxic CTF1 fragments. Both effects can result from a reduction of c-secretase cleavage activity at the e site of substrates suggesting that increasing c-secretase cleavage activity may be of therapeutic interest in PS FAD cases [6] . Interestingly, recent clinical trials showed that inhibition of Ab production by c-secretase inhibitors (GSI) was associated with toxicity in treated patients [15] , an observation consistent with the reduced production of CTF2 peptides and increased accumulation of toxic CTF1 fragments expected from the inhibition of csecretase activity by the GSIs [5] ; see also Fig. 1 . Thus, GSIs may act in vivo similar to PS FAD mutations. Both may cause toxicities by a double hit, reducing production of functionally important CTF2 peptides and increasing the levels of toxic CTF1 protein fragments.
Finally, there is evidence that in addition to their role in c-secretase proteolysis, PSs have c-secretase-independent functions including stimulation of the PI3 K/Akt cell survival signaling, regulation of GSK-3 kinase [4] and calcium homeostasis [45] . Importantly, a number of PS1 FAD mutations have been reported to interfere with c-secretaseindependent functions of PS1, revealing additional mechanisms by which these mutations may promote neurodegeneration and tau overphosphorylation [3, 24, 35] .
In summary, the main mechanisms responsible for the neurodegeneration of AD are still poorly understood. It is unclear for example why certain neuronal populations such as cholinergic neurons are more vulnerable to AD than other neurons and how risk factors like the apoE4 allele, the process of aging, and genetic FAD mutations promote specific degeneration of these neuronal populations. There are additional indications that environmental factors such as oxidative stress and inflammatory processes may also contribute to the neuronal cell death of AD [34, 48] . Thus although it is clear that FAD is caused by specific genetic legions, it is reasonable to assume that in the majority of cases such as sporadic AD, the final outcome is determined by both genetic and environmental factors. Presently the FAD mutations are the only identifiable causative agents of AD and these mutations may offer the best available models for the study of the cellular and molecular mechanisms involved in the development of the more common sporadic disease. Since the clinical manifestations and neuropathology are similar in both sporadic and familial AD, lessons learned from studying the mechanisms of FAD should also be applicable to sporadic AD.
